Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

Paavonen, JormaJormaPaavonenJenkins, DavidDavidJenkinsBosch, F XavierF XavierBoschNaud, PauloPauloNaudSalmerón, JorgeJorgeSalmerónWheeler, Cosette MCosette MWheelerSONG-NAN CHOWApter, Dan LDan LApterKitchener, Henry CHenry CKitchenerCastellsague, XavierXavierCastellsaguede Carvalho, Newton SNewton Sde CarvalhoSkinner, S RachelS RachelSkinnerHarper, Diane MDiane MHarperHedrick, James AJames AHedrickJaisamrarn, UnnopUnnopJaisamrarnLimson, Genara AmGenara AmLimsonDionne, MarcMarcDionneQuint, WimWimQuintSpiessens, BartBartSpiessensPeeters, PascalPascalPeetersStruyf, FrankFrankStruyfWieting, Susan LSusan LWietingLehtinen, Matti OMatti OLehtinenDubin, GaryGaryDubin2023-02-172023-02-172007-06-3001406736https://scholars.lib.ntu.edu.tw/handle/123456789/628283The aim of this interim analysis of a large, international phase III study was to assess the efficacy of an AS04 adjuvanted L1 virus-like-particle prophylactic candidate vaccine against infection with human papillomavirus (HPV) types 16 and 18 in young women.en[SDGs]SDG3Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialjournal article10.1016/S0140-6736(07)60946-5176027322-s2.0-34250850161https://api.elsevier.com/content/abstract/scopus_id/34250850161